Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: Final results of the ALL-4 randomized, phase III trial of the EORTC leukemia group

Haematologica

Volumn 95, Issue 9, 2010, Pages 1489-1495

  Labar, Boris ^a   Suciu, Stefan ^b   Willemze, Roel ^c   Muus, Petra ^d   Marie, Jean Pierre ^e   Fillet, Georges ^f   Berneman, Zwi ^g   Jaksic, Branimir ^h   Feremans, Walter ⁱ   Bron, Dominique ^j   Sinnige, Harm ^k   Mistrik, Martin ^l   Vreugdenhil, Gerard ^m   De Bock, Robrecht ⁿ   Nemet, Damir ^a   Gilotay, Caroline ^b   Amadori, Sergio ^o   De Witte, Theo ^c  

^a KBC Zagreb   (Croatia)

^b EORTC DATA CENTER   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HÔTEL DIEU   (France)

^f Antwerp University Hospital ^*  (Belgium)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h University of Zagreb   (Croatia)

ⁱ ERASME HOSPITAL   (Belgium)

^j JULES BORDET INSTITUTE   (Belgium)

^k JEROEN BOSCH HOSPITAL   (Netherlands)

^l UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^m MÁXIMA MEDICAL CENTER   (Netherlands)

ⁿ AkademischZiekenhuis   (Belgium)

^o UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Adult ALL; Dexamethasone; Lymphoblastic lymphoma; Prednisolone; Randomized trial

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; REMISSION INDUCTION; YOUNG ADULT;

EID: 77956847722     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.018580     Document Type: Article

References (31)

1. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17(1):1-12.
2. Smith M, Arthur D, Camitta B Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14:18-24.
3. Visser JH, Wessels G, Hesseling PB, Louw I, Oberholster E, Mansvelt EP. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001; 18(3):187-191.
4. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol. 2002; 6(2):114-141.
5. Pui CH, Ewans WE. Treatment of acute lymphoblastic leukaemia. N Engl J Med. 2006;354(2):166-178.
6. Cantrill HL, Waltman SR, Palberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab. 1975;40(6):1073-1077.
7. Kaspers GJ, Veerman AJ, Popp-Snijders C, Lomecky M, Van-Zantwijk CH, Swinkels LM, Van-Werin ER. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukaemia. Med Ped Oncol. 1996;27(2):114-121.
8. Balis FM, Lester CM, Chrousos GP, Heideman RI, Poplak DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukaemia. J Clin Oncol. 1987;5(2):202-207.
9. Jones B, Freeman AL, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukaemia when prednisolone is replaced by dexamethasone in the treatment of acute lymphoblastic leukaemia. Med Ped Oncol. 1991:19(4): 269-275.
10. Veerman AJ, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911-918.
11. Silverman LB, Gelber RD, Dalton VK, Young ML, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of the Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5):1211-1218.
12. Hurwitz C, Silverman LB, Schorin MA, Clavell LA, Dalrton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukaemia. Cancer. 2000;88(8):1964196-9.
13. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729-735.
14. De Witte T, Awwad B, Boezeman J, Schattenberg A, Muus P, Raemaekers J, et al. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994;14(5): 767-774.
15. Gökbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, et al. Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14(6):1307-1325.
16. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Statistics for Biology and Health. Springer-Verlag, New-York. 1997.
17. Gray RJ. A class of K-sample tests for comparing he cumulative incidence of a competing isk. Ann Stat. 1988;16:1141-1154.
18. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from Children Cancer Group. Blood. 2003; 01(10):3809-3817.
19. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TOB, on behalf of the Medical Research Council Childhood Leukemia Working Group. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-745.
20. de Vries MA, van Litsenburg RR, Huisman J, Grootenhuis MA, Versluys AB, Kaspers GJ, Gemke RJ. Effect of dexamethasone on quality of life in children with acute lymphoblastic lekaemia: a prospective observational study. Health Qual Life Outcomes. 2008;6:103.
21. Pui CH, Campana D. Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia. Leukemia. 2007; 21(4):593-594.
22. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-3767.
23. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, et al. Long term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukaemia. 2000;14(12):2193-2194.
24. Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia. 2000;14(3):356-363.
25. Goekbuget N, Bauer KH, Beck J, Diedrich H, Lamprecht M, Leimer L, et al. Dexamethasone dose and schedule significantly influences remission rate and toxicity of induction therapy in adult acute lymphoblastic leukemia (ALL): results of the GMALL pilot trial 06/99. Blood 2005; 106:1832 (abstr).
26. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-2801.
27. Ito C, Evans WE, McNinch L, Coustan- Smith E, Mahmoud H, Pui CH, Campana D. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14(8):2370-2376.
28. Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al- Jefri A, Al-Musa AR, Saleh M, et al. Dexamethasone-associated toxicity during induction therapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003; 97(11):2898-2903.
29. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Peetermans M, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia for leukemia for patients < 50 years in first complete remission: results of the EORTC ALL-3 trial. Haematologica. 2004;89(7):809-817.
30. Willemze R, Labar B. Postremission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Semin Hematol. 2007;44(4): 267-273.
31. Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G, Rabusin M. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009; 53(6):984-991.